RemeGen Looks to Take Next Global Steps During ASN Kidney Week 2022

ORLANDO, FL – RemeGen officials look to partner with a global pharmaceutical or biotech company to take their drug candidates to the next level during ASN Kidney Week 2022.

“Having seen a lot of promising data having emerged from the completed, or even ongoing trials, it really brings us to looking at the next steps as to how we can further the development of the very promising drug candidates,” Catherine Cheung, RemeGen senior director of global clinical operations, said on the first day of the American Society of Nephrology (ASN) event. “We are really looking for that strong partnership with a global pharmaceutical company or biotech to further the development in the global landscape.”

RemeGen joined 140 kidney-research companies participating in the exposition, the first in-person event since 2019, which drew thousands of participants.

“RemeGen Biosciences, having established in 2008, has developed fully integrated, end-to-end, R-and-D platforms that cover the full key functions of biologics development,” Cheung said. “With this robust platform outputs roughly 20 drug candidates to date that span three specialized platforms. One is the Antibody and Fusion Protein Platform, the Antibody-Drug Conjugate (ADC) Platform as well as the Bifunctional Antibody (HiBody) Platform.”

“From these various technology platforms, the company has successfully developed a few key drug assets, mainly the Telitacicept or RC18 with six to seven indications in development in the autoimmune disease space. Specifically for lupus being its first indication that has gone into a global phase of restudy. Also, Telitacicept has received approval in China that leads to its further global expansion.” She continued: “IgAN is the next indication that the company is expanding its global development efforts. The drug candidates are also addressing oncology and ophthalmology disease areas as well.”

Company officials featured three of its drug candidates in these three areas:

• Autoimmune Diseases – Its Telitacicept (RC18), which is a TACI-Fc fusion protein for injection that targets two important cell-signaling molecules, B-cell lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). Telitacicept is in the commercial or clinical trials stage in the autoimmune disease area and for the treatment of systemic lupus erythematosus (SLE).
• Oncology – Its Disitamab Vedotin (RC48) is the first Chinese ADC drug developed by RemeGen to receive breakthrough designations in both the US and China for the treatment of gastric cancer.
• Ophthalmology – RC28 is a potential VEGF-FGF dual-targeting fusion protein for treating eye diseases. It has completed a phase 1 dose-escalation study in patients with wet age-related macular degeneration in China.

RemeGen was founded in 2008 in China, and its US branch, RemeGen Biosciences, has offices in California and Maryland.

Cheung said the Kidney Week exposition is a great venue for finding RemeGen’s next strategic partner to bring its biologics to a global scale.

Author

GeneOnline